1,4-Di(propan-2-yl)-4,5-dihydrotriazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 1,4-Di(propan-2-yl)-4,5-dihydrotriazole
• 英文别名: 1,4-di(propan-2-yl)-4,5-dihydrotriazole
• 化学式: C₈H₁₇N₃
• 分子量: 155.24
• InChiKey: NWXBSMIKNPPYJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] LAPACHONE DERIVATIVES CONTAINING TWO REDOX CENTERS AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE LAPACHONE CONTENANT DEUX CENTRES REDOX ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV TEXAS

  公开号：WO2017070012A1

  公开（公告）日：2017-04-27

  Provided herein are compounds containing two redox centers including a chalcogen redox center of the formula: wherein: R1, R2, X1, X2, Y1, and m are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

  本文提供了含有两个氧化还原中心的化合物，其中包括一个硫属氧化还原中心，其化学式如下：其中：R1、R2、X1、X2、Y1和m如本文所定义。本文还提供了所述化合物的药物组合物以及使用这些化合物进行治疗的方法，包括它们在癌症治疗中的应用。
• Lipid-Conjugated Rhamnose for Immune System Recruitment and Oncotherapy
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20140112975A1

  公开（公告）日：2014-04-24

  L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions.

  L-岩藻糖抗原-脂质共轭物用于招募免疫系统到肿瘤生长部位，以启动抗肿瘤抗原反应。介绍L-岩藻糖抗原共轭脂质进入细胞膜的方法，使L-岩藻糖抗原显示在细胞表面。细胞可以是肿瘤细胞，更具体地可以是黑色素瘤细胞。将细胞与一个或多个L-岩藻糖抗原-脂质共轭物接触，使L-岩藻糖抗原-脂质共轭物插入细胞膜。例如，可以通过肿瘤内注射接触细胞。含有L-岩藻糖抗原-脂质共轭物的制药组合物和使用共轭物和组合物的治疗方法。
• [EN] HETEROARYL INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] INHIBITEURS HÉTÉROARYLE DE LA KALLICRÉINE PLASMATIQUE
  申请人：SHIRE HUMAN GENETIC THERAPIES

  公开号：WO2022197758A1

  公开（公告）日：2022-09-22

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了一种化合物及其组合物，可用作血浆卡利肌酶的抑制剂，并表现出相同的理想特性。
• MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20200121806A1

  公开（公告）日：2020-04-23

  Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
• US9861702B2
  申请人：——

  公开号：US9861702B2

  公开（公告）日：2018-01-09